usp7

USP7-IN-7, a potent USP7 inhibitor, exhibits an IC50 value of <10 nM. Demonstrating cytotoxicity against both p53-mutant and p53 wild-type blood cancer, as well as neuroblastoma cell lines at low nanomolar concentrations, it holds potential for cancer research applications.

Benzamide, 4-[6-amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridinyl]-N-methyl- is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM. USP7-IN-8 (GNE-6776) has anticancer effects.

USP7-IN-1 is a selective and reversible inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 77 μM.

USP7-IN-10 hydrochloride, also known as compound 1, is a potent inhibitor of the enzyme ubiquitin-specific protease 7 (USP7), exhibiting an IC50 value of 13.39 nM [1].

USP7-IN-10 is a potent inhibitor of ubiquitin-specific protease 7 (USP7), exhibiting an inhibition concentration half-maximal (IC50) value of 13.39 nM.

USP7-IN-9, a potent inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 40.8 nM, effectively induces apoptosis and arrests cell progression at the G0/G1 and S phases in RS4;11 cells. It decreases the protein levels of oncoproteins MDM2 and DNMT1 while enhancing the levels of tumor suppressors p53 and p21.

USP7-IN-12 (compound 1) is a potent, orally active Usp7 inhibitor with an IC50 of 3.67 nM, demonstrating antiproliferative activity [1].

USP7 USP47 inhibitor (USP7 47 inhibitor-1) is a selective ubiquitin-specific protease 7 47 (USP7 USP47) inhibitor, with EC50s of 0.42 μM and 1.0 μM, respectively.

USP7-IN-3 is a potent and selective allosteric inhibitor of ubiquitin-specific protease 7 (USP7).

USP7-IN-13 (Compound 101), a USP7 inhibitor, exhibits an IC50 range of 0.2-1 μM and is applicable in researching multiple myeloma [1].

USP7-IN-4 is a highly potent and selective allosteric USP7 inhibitor.

USP7-IN-6 is a potent inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 6.8 nM.

USP8-IN-2 is a potent inhibitor of the deubiquitinating enzymes USP7 and USP8, with an IC50 of 4.0 μM against USP8D. USP8-IN-2 is a potential compound for the treatment of cancer and viral infections.

P22074 is a USP7 inhibitor. It is not an active antagonist like its halogenated related compounds. p22074 has antitumour activity.

USP28-IN-4 is a potent USP28 inhibitor with an IC50 value of 0.04 μM against USP28. USP28-IN-4 exhibits anticancer activity and inhibits USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 is cytotoxic to human colorectal and lung squamous carcinoma cells and dose-dependently downregulates c-Myc cellular levels through the ubiquitin-proteasome system. -proteasome system to dose-dependently downregulate cellular levels of c-Myc.

USP28-IN-3 is a highly selective USP28 inhibitor with an IC50 value of 0.1 μM against USP28.USP28-IN-3 exhibits anticancer activity and inhibits USP2, USP7, USP8, USP9x, UCHL3, and UCHL5.USP28-IN-3 is cytotoxic to human colorectal and lung squamous carcinoma cells, inhibiting c-cells and c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-cells through the ubiquitin-proteasome system. -proteasome system to dose-dependently downregulate cellular levels of c-Myc.

P005091 (P5091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM.

FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM).

P 22077 (P22077) is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM. It also inhibits the closely related USP47.

BAY 11-7082 (BAY 11-7821) is an NF-κB inhibitor that suppresses TNFα-induced IκBα phosphorylation (IC50=10 μM) and also inhibits the ubiquitin-specific proteases USP7 and USP21 (IC50=0.19 0.96 μM).

GNE-6640 is a non-covalent inhibitor targeting ubiquitin specific peptidase 7 (USP7), exhibiting IC50 values of 0.75 μM for full-length USP7, 0.43 μM for the USP7 catalytic domain, 20.3 μM for full-length USP43, and 0.23 μM for Ub-MDM2, respectively.

HBX 41108 (HBX-41108) is a non-competitive, reversible inhibitor of USP7 with an IC50 of 424nM. HBX 41108 inhibited deubiquitination of p53 mediated by USP7 in a dose-dependent manner with an IC50 of 0.8μM.

HBX 19818 is a specific ubiquitin-specific protease 7 (USP7) inhibitor (IC50: 28.1 μM).

ALM2 is an USP7 inhibitor.

HBX is a deubiquitinase inhibitor. It inhibits HAdV type 5 (species C, HAdV-C5) replication and oncogenic transformation through inhibition of the cellular pro-viral factor ubiquitin-specific protease 7 (USP7). HBX also significantly inhibits virus genome replication and progeny release of all adenovirus types tested, with the exception of types 12 and 31, from tested species.

FT827 is a covalent inhibitor of selective ubiquitin-specific protease 7 (USP7) (Ki=4.2 µM, Kd=7.8 µM) targeting the catalytic center of the autoinhibitory apolipoprotein form of USP7 for cancer research.

NSC-632839 (Ubiquitin Isopeptidase Inhibitor II) is a nonselective isopeptidase inhibitor, which inhibits USP2 (EC50: 45±4 μM), USP7 (EC50: 37±1 μM), and SENP2 (EC50: 9.8±1.8 μM).

XL177A is a selective irreversible USP7 inhibitor(IC50 : 0.34 nM). XL177A elicits cancer cell killing through a p53-dependent mechanism.

USP28-IN-2 is a selective USP28 inhibitor (IC50 = 0.3 μM), demonstrating high specificity compared to USP2, USP7, USP8, USP9x, UCHL3, and UCHL5. This compound exhibits cytotoxic effects on cancer cells and induces the degradation of c-Myc via the ubiquitin-proteasome pathway. Additionally, USP28-IN-2 reduces ankyrin-1 2 levels in vitro and potentiates the responsiveness of colorectal cancer cells to Regorafenib [1].

USP8-IN-3 is a potent inhibitor of the deubiquitinating enzymes USP7 and USP8, with IC50 of 4.0 μM against USP8D. USP8-IN-3 inhibited the proliferation of GH3 and H1957 cells with GI50 values of 37.03 μM and 6.01 μM, respectively. USP8-IN-3 is a potential compound for the treatment of cancer and viral infections.

USP7 inhibitor

HBX28258 is a recombinant human USP7 protein inhibitor. In human colon cancer and embryonic kidney cell, it acts by binding the active site through a covalent mechanism and selectively inactivating USP7 protein.

RMPI-8226-38 is an irreversible inhibitor of USP7 with IC50 value of 22 uM against RMPI-8226.

(R)-FT671 is the R-isomer of FT671, a potent, non-covalent, and selective inhibitor of USP7 with an IC50 of 52 nM.

XL-188 is a highly potent and selective inhibitor of USP7. XL188 inhibited USP7 catalytic domain and full-length enzyme with IC50 values of 193 and 90 nM, respectively. XL188 Promotes USP7-Dependent Loss of HDM2 and Increase of p53 and p21. XL188 represents one of only a small set of mammalian DUB inhibitors with low nanomolar potency and a high degree of selectivity relative to other DUBs

U7D-1, a groundbreaking and selective ubiquitin-specific protease 7 (USP7) PROTAC degrader, exhibits a DC50 value of 33 nM in RS4;11 cells, demonstrating its potent anticancer properties. Furthermore, U7D-1 effectively induces apoptosis in Jeko-1 cells [1].

GNE-6776 is a selective USP7 inhibitor.